New Wegovy 7.2mg Dose UK: What You Need to Know (January 2026 Approval)

In January 2026, the MHRA granted approval for a new, higher dose of semaglutide (Wegovy) — 7.2mg weekly. The UK became the first country in the world to approve this dose. That is not a trivial distinction: it means UK prescribers now have access to an option that delivers meaningfully greater weight loss than the existing 2.4mg maintenance dose, for patients who have not achieved sufficient response.

What Is the 7.2mg Dose?

The current standard Wegovy dose titration runs from 0.25mg weekly up to 2.4mg weekly over approximately 16 weeks. The 7.2mg dose is a new, higher maintenance option — approximately three times the existing maintenance dose — intended for patients who have been on 2.4mg for at least 12 weeks and have not achieved the expected weight loss response.

This is not a dose anyone starts on. It follows the same incremental approach: patients titrate up from 2.4mg through intermediate steps before reaching 7.2mg. The safety profile at higher doses requires careful monitoring, which is why prescriber oversight is essential.

The STEP UP Trial Data

The 7.2mg approval was supported by data from the STEP UP trial, which directly compared higher-dose semaglutide against the existing 2.4mg dose in adults who had not achieved adequate response.

A 6 percentage point difference in absolute weight loss is significant in practice. For someone weighing 110kg, the difference between 2.4mg and 7.2mg could mean an additional 6-7kg of weight loss at the same timepoint. For patients who have plateaued or who need greater metabolic improvement to address cardiovascular or metabolic risk, that gap matters.

The side effect profile at 7.2mg is consistent with semaglutide at lower doses — predominantly gastrointestinal, predominantly early in dose titration. Nausea rates were higher than at 2.4mg, as would be expected, but serious adverse events were not significantly elevated.

Who Is the 7.2mg Dose For?

The MHRA approval is not blanket permission to prescribe 7.2mg as a first-line dose. The intended population is:

Adults who:

• Are already established on semaglutide 2.4mg (Wegovy)
• Have been on the 2.4mg maintenance dose for at least 12 weeks
• Have achieved less than the expected 5-10% weight loss response at 2.4mg
• Do not have contraindications that preclude a higher dose (personal/family history of medullary thyroid carcinoma, MEN2 syndrome, severe GI disease)
• Have been assessed by a prescriber as clinically appropriate for dose escalation

There is also a pharmacogenomic dimension worth noting. Research is ongoing into why some patients respond poorly to semaglutide 2.4mg despite good adherence. Higher doses may overcome some of this variability, but this is an active research area and not yet a clinical tool for routine use.

How Does 7.2mg Compare to Mounjaro at 15mg?

This is the obvious question. The SURMOUNT-1 trial showed tirzepatide 15mg producing 20.9% weight loss at 72 weeks. Wegovy 7.2mg data shows 20.7%. On face value, they are nearly identical.

The distinction that matters: Wegovy at 7.2mg carries the same cardiovascular outcomes data as standard Wegovy (SELECT trial), because the mechanism is the same. Mounjaro at 15mg does not yet have comparable cardiovascular outcomes data.

For patients where cardiovascular risk reduction is a primary clinical goal, Wegovy 7.2mg offers both the higher weight loss of a maximum-dose GLP-1 and the SELECT-proven MACE reduction. That is a unique combination in the current landscape.

The SURMOUNT-5 Head-to-Head Context

The recently published SURMOUNT-5 trial compared Mounjaro directly against Wegovy (standard 2.4mg dose) in a head-to-head randomised trial. Mounjaro 20.2% vs Wegovy 13.7% (NEJM 2025, DOI 10.1056/NEJMoa2500439).

That comparison used standard 2.4mg Wegovy. It predates the 7.2mg approval. A future head-to-head between Mounjaro 15mg and Wegovy 7.2mg would be genuinely informative — and that trial does not yet exist.

The honest interpretation of current data: at their respective maximum approved doses, Wegovy 7.2mg and Mounjaro 15mg are likely to produce similar weight loss. The choice between them for an individual patient will increasingly rest on side effect tolerance, cost, cardiovascular history, and prescriber preference.

Accessing 7.2mg Wegovy in the UK

The 7.2mg dose is newly approved, and real-world availability through NHS pathways is still catching up with the regulatory decision. In practice, this means:

NHS: NICE guidance on the 7.2mg dose is still being finalised as of mid-2026. NHS prescription of the 7.2mg dose requires a prescriber to make a case under the clinical governance pathway, and formulary inclusion varies by ICB. If you are on the NHS Wegovy pathway at 2.4mg and have had a suboptimal response, ask your prescriber specifically about dose escalation.

Private clinics: Most regulated online prescribing services are now able to offer the 7.2mg dose for eligible patients who are already established on 2.4mg with documented treatment history. The prescriber must assess eligibility — you cannot simply request a higher dose.

For details on the existing Wegovy 2.4mg dose schedule and what the standard titration looks like, see /guides/wegovy-7-2mg-dose-guide, which covers the full pre-7.2mg escalation pathway.

If you are looking for a UK prescriber who can assess eligibility for Wegovy including the 7.2mg dose, see /guides/best-glp1-prescriber-uk-2026.

Side Effects at the Higher Dose

Expect more gastrointestinal side effects during titration to 7.2mg than you experienced going up to 2.4mg. Nausea, vomiting, and diarrhoea are all more common at higher doses. These are typically most pronounced in the first 1-4 weeks after each dose increase, and diminish as the body adjusts.

Practical steps to manage this:

• Eat smaller portions at each meal — appetite suppression is stronger at 7.2mg
• Avoid fatty, rich, or spicy foods during the titration period
• Inject at the same time each week — some patients find evening injections reduce daytime nausea
• Slow the titration if side effects are severe — your prescriber can pause at an intermediate dose

For a detailed guide on managing nausea specifically, see /guides/nausea-remedies-ozempic-uk.

What the 7.2mg Approval Signals

The MHRA's decision reflects a shift in how obesity is being treated pharmacologically. The old model assumed that higher doses of GLP-1 drugs would face prohibitive safety barriers. The STEP UP data showed that is not the case — higher doses are tolerable, with additional weight loss that matters clinically.

This pattern mirrors what happened with insulin dosing decades ago: the clinical goal determines the appropriate dose, not an arbitrary ceiling. As more long-term safety data accumulates on semaglutide, and as SURPASS-CVOT reports on tirzepatide, the therapeutic picture will continue to sharpen.

For now, the 7.2mg dose is a meaningful new option for patients who have done everything right at 2.4mg and still need more. It is not the right choice for everyone — and it is not a shortcut. But for the right patient, with the right prescriber, it fills a genuine gap.

For cost comparison between Wegovy and Mounjaro, including the higher-dose options, see /guides/mounjaro-vs-wegovy-cost-comparison.